Attaining sinus rhythm mediates improved outcome with early rhythm control therapy of atrial fibrillation: the EAST-AFNET 4 trial

Lars Eckardt 1,2‡, Susanne Sehner3†, Anna Suling3, Katrin Borof4, Guenter Breithardt 1,2, Harry Crijns 5, Andreas Goette 2,6, Karl Wegscheider 2,3,7, Antonia Zapf3,7, John Camm 8, Andreas Metzner 4,7, and Paulus Kirchhof 2,4,7,9*

1Department of Cardiology II (Electrophysiology), University Hospital Münster, Münster, Germany; 2Atrial Fibrillation Network (AFNET), Münster, Germany; 3Institute of Medical Biometry and Epidemiology, University Medical Center Hamburg–Eppendorf, Germany; 4Department of Cardiology, University Heart and Vascular Center, University Medical Center Hamburg–Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany; 5Department of Cardiology, Maastricht University Medical Center and Cardiovascular Research Institute Maastricht, Maastricht, The Netherlands; 6Department of Cardiology, Vincenz-Krankenhaus Paderborn, Paderborn, Germany; 7DZHK (German Center for Cardiovascular Research), partner site Hamburg/Kiel/ Luebeck, Berlin, Germany; 8Cardiology Clinical Academic Group, Molecular and Clinical Sciences Research Institute, St. George’s University of London, London, UK; and 9Cardiovascular Sciences, University of Birmingham, Birmingham, UK

Received 6 July 2022; revised 10 August 2022; accepted 12 August 2022; online publish-ahead-of-print 29 August 2022

See the editorial comment for this article ‘Sinus rhythm: the sine qua non for rhythm control?’, by Dominik Linz and William F. McIntyre, https://doi.org/10.1093/eurheartj/ehac490.

Abstract

Aims
A strategy of systematic, early rhythm control (ERC) improves cardiovascular outcomes in patients with atrial fibrillation (AF). It is not known how this outcome-reducing effect is mediated.

Methods and results
Using the Early treatment of Atrial Fibrillation for Stroke prevention Trial (EAST—AFNET 4) data set, potential mediators of the effect of ERC were identified in the total study population at 12-month follow up and further interrogated by use of a four-way decomposition of the treatment effect in an exponential model predicting future primary outcome events. Fourteen potential mediators of ERC were identified at the 12-month visit. Of these, sinus rhythm at 12 months explained 81% of the treatment effect of ERC compared with usual care during the remainder of follow up (4.1 years). In patients not in sinus rhythm at 12 months, ERC did not reduce future cardiovascular outcomes (hazard ratio 0.94, 95% confidence interval 0.65–1.67). Inclusion of AF recurrence in the model only explained 31% of the treatment effect, and inclusion of systolic blood pressure at 12 months only 10%. There was no difference in outcomes in patients who underwent AF ablation compared with those who did not undergo AF ablation.

Conclusion
The effectiveness of early rhythm control is mediated by the presence of sinus rhythm at 12 months in the EAST-AFNET 4 trial. Clinicians implementing ERC should aim for rapid and sustained restoration of sinus rhythm in patients with recently diagnosed AF and cardiovascular comorbidities.
Structured Graphical Abstract

Key Question
Which component or mediator of early rhythm control therapy conveys the reduction in cardiovascular death, stroke, or hospitalization for heart failure or acute coronary syndrome, in the EAST-AFNET 4 trial?

Key Finding
The presence of sinus rhythm at 12 months explained 81% of the effect of early rhythm control on preventing cardiovascular outcomes. Other factors, e.g., blood pressure, recurrent atrial fibrillation (AF), or AF ablation, only explained small portions of the effect.

Take Home Message
Clinicians implementing early rhythm control to prevent cardiovascular complications of atrial fibrillation should aim for rapid and sustained restoration of sinus rhythm in patients with recently diagnosed AF and cardiovascular comorbidities.

Introduction
The Early treatment of Atrial Fibrillation for Stroke prevention Trial (EAST-AFNET 4) demonstrated that a strategy of systematic initiation of early rhythm control (ERC) reduced cardiovascular outcomes by 21% compared with usual care. Several prespecified subanalyses, including comparisons of patients with and without heart failure, with and without symptoms, and patients with different atrial fibrillation (AF) patterns, did not identify a differential effectiveness of ERC. The general safety of ERC has recently also been corroborated by

The EAST-AFNET 4 trial data set was analysed for potential mediators of the outcome-reducing effect of the early rhythm control strategy in the trial. All factors that were different between randomized groups at the 12-month visit were considered. Attaining sinus rhythm explained most of the treatment effect in a landmark analysis considering the remaining 4.1 follow-up years. In conclusion, clinicians aiming to implement early rhythm control should try to attain sinus rhythm.

Keywords
Atrial fibrillation • Rhythm control • AF ablation • Antiarrhythmic drugs • Stroke • Randomized trials • Mediator analysis
analyses in large observational data sets. Based on the inclusion criteria of the EAST-AFNET 4 trial, the majority of patients with new-onset AF are eligible for ERC. The results have started to shift the use of rhythm control therapy from a symptom-driven therapy to a risk-reducing strategy aiming at restoring and maintaining sinus rhythm as the default therapy in patients with recently diagnosed AF and stroke risk factors.

EAST-AFNET 4 tested ERC as a therapy strategy. There has been much speculation on the drivers of the reduction in outcomes within this treatment strategy. The availability of AF ablation, improvements in the safe use of antiarrhythmic drugs, including patients with heart failure, continuation of improved oral anticoagulation, and therapy of concomitant conditions irrespective of achieved rhythm, and the early initiation of rhythm control with the associated prevention of severe forms of atrial cardiomyopathy, have been discussed. To identify possible factors associated with prevention of cardiovascular outcomes on ERC therapy, we scrutinized the EAST-AFNET 4 trial data set for factors and mediators of ERC that are associated with reduced cardiovascular outcomes.

Methods

Sample characteristics of the available patients are given as absolute and relative frequencies, mean ± standard deviation or as median with interquartile range. A two-tailed P < 0.05 was considered to be statistically significant. The reported P-values and confidence intervals (CIs) have not been adjusted for multiplicity. All analyses were conducted with Stata software (StataCorp 2021, Stata Statistical Software: Release 17; StataCorp LLC, College Station, TX, USA) and the package med4way.

For model building, missing values in medical relevant baseline variables as well as follow-up data of medication, recurrent AF, blood pressure, and secondary endpoints were multiply imputed with 65 repetitions following the recommendations of White et al. As in the primary analysis of the EAST trial, missing values were imputed in survivors only, except of the EQ-5D visual analogue scale where deceased patients received a score of 0.

All analyses were adjusted for medical relevant baseline variables to reduce potential confounding bias: age, gender, centre type (D or A site), European Heart Rhythm Association (EHRA) score, New York Heart Association (NYHA) class, prior stroke or transient ischaemic attack, AF pattern, left atrial diastolic diameter, MoCA (Montréal Cognitive Assessment) score, arterial hypertension, diabetes, peripheral artery disease, severe coronary artery disease (previous myocardial infarction, coronary artery bypass graft, or percutaneous coronary intervention), left ventricular hypertrophy on echocardiography (>15 mm wall thickness), left ventricular ejection fraction, AF duration at baseline (categorized <10, 10–100, and >100 days), chronic obstructive pulmonary disease, chronic kidney disease (Modification of Diet in Renal Disease Stage III or IV), physical and mental SF-12 component summary scores, and cardiac rhythm.

Objective 1

A causal mediation analysis was conducted in the total study population to identify mediators of treatment success with respect to the primary outcome parameter and two of its key components, cardiovascular death and stroke. In this modelling approach, the overall effect of a treatment on the outcome is decomposed into a direct effect and a pathway via a potential mediator. This pathway is determined by the effect of the treatment on the mediator and the effect of the mediator on the outcome, which may depend on the treatment group (treatment–mediator interaction). Thus, it may be that the mediator itself modifies the treatment effect when it is present. The ongoing treatment may be more (or less) advantageous for patients depending on the mediator, i.e. the mediator may moderate the treatment effect. Potential mediators of treatment effect are thus variables that are affected by the treatment and associated with the outcome. This four-way decomposition allows to estimate different effects:

- The total effect (TE) is an estimate of the treatment effect on the outcome, adjusted for potential confounders, taking the considered mediators into regard.
- The natural direct effect estimates the adjusted treatment effect on the outcome not caused by changes in the mediator.
- The controlled direct effects (CDE(m)) at Level m quantifies the adjusted treatment effect on the outcome not caused by changes in the mediator.
- The proportion eliminated (PE = (TE-CDE(m))/TE) is a measure that reflects the importance of a mediator for the explanation of the treatment effect if moderation effects are additionally taken into regard.

The outcome of interest in the mediation model is the time to the first primary endpoint occurring after the 12-month visit. We estimated the treatment and the mediator effect on the outcome using an accelerated failure time regression with an exponential distribution allowing to convert acceleration effects to hazard ratios (HRs). We selected the first in-person follow-up visit at 12 months (12-month follow up) as the survey time of potential mediators. All patients who had experienced the first primary endpoint by this time, who died or who had withdrawn their consent by then, were excluded from the mediation analysis. Later survey times would have led to a further reduction of the analysable sample and a loss of statistical power.

First, we examined all clinically meaningful parameters captured at 12-month follow up to determine the extent to which they were influenced by treatment. This was done by testing the difference in the 12-month measurement between randomized groups using adjusted mixed linear, mixed logistic, mixed ordinal (with site as random effect), or multinomial logistic regression, where appropriate. All models were further adjusted for the respective baseline measurement, if available. From the list of these potential mediators, we selected all variables with significant differences between the treatment groups to perform separate mediation analyses in a second step. Parameters that are a direct reflection of the intervention, e.g. echocardiography (ECG) changes reflecting antiarrhythmic drug therapy or complications of AF ablation, were not carried forward. The results of the mediation analyses are presented as HR with corresponding 95% CI of a landmark analysis with the first in-person follow-up visit at 12 months as the starting point.

To determine the effects of AF ablation on the primary outcome, we performed two further analyses studying ablation as a time-dependent variable.

Objective 2

In a first step, we investigated the effect of ablation in the total study population using a Cox model with a time-dependent variable for ablation and an interaction term between treatment group and ablation to consider that the indication for an ablation was not the same in the two random groups. In this model, we also included all two-way interactions between adjusting baseline covariates and treatment group taking into account that the covariates may act differently in the random groups. We did a backwards selection (selection criterion $P < 0.01$) using likelihood ratio tests. As no interaction with treatment group showed a $P$-value $<0.01$, the adjusting baseline covariates remained in the model as main effects.

To describe the ablation effect within the ERC and usual care group, the respective contrasts of the two-way interaction between ablation and treatment groups were estimated and presented as HR with corresponding 95% CI.

Objective 3

In a second step, we examined if there is a difference between early (delivered within 8 weeks after randomization) or late ablation (delivered...
4130

L. Eckardt et al.

>8 weeks after randomization). This analysis was restricted to the ERC patients only because the predominant indication for ablation differed between the random groups and there were only nine patients with early ablations in the usual care group. We used a Cox model with two time-dependent covariates. This analysis compared all periods after early ablation or late ablation with all periods without ablation, controlling for patient characteristics. Results are presented as HR together with 95% CI.

Results

Mediators of early rhythm control leading to improved cardiovascular outcomes (Objective 1)

A total of 1257/1395 (90%) patients randomized to ERC and 1260/1394 (90%) patients randomized to usual care were seen at the 12-month visit without reaching a first primary outcome event (Figure 1). Analysis of all parameters captured at that visit identified 14 potential mediators of the treatment effect on the outcome (Table 1). The effects of ERC on these parameters at 12 months were determined. Systolic blood pressure, sinus rhythm at 12 months, and no recurrence of AF up to 12 months were significantly different between random groups (Table 1).

To determine the effect of these mediators on outcomes, we conducted a landmark analysis evaluating all first primary outcome events after the 12-month visit. Early rhythm control reduced the first primary outcome from 12 months on up to the study end (median follow-up time 4.1 years, HR 0.73, 95% CI 0.61–0.92; Figure 2). Sinus rhythm at 12 months explained 81% of the treatment effect of ERC therapy compared with usual care during the remainder of follow-up. In patients not in sinus rhythm at 12 months, ERC did not reduce further cardiovascular outcomes. Atrial fibrillation recurrence in the first 12 months of follow-up only explained 31% of the treatment effect, systolic blood pressure at the 12-month visits only 10% (Table 2). For cardiovascular death and stroke, two key components of the primary outcome, similar effects were observed with larger CI due to smaller event numbers (Table 2). The key mediator ‘sinus rhythm at 12 months’ was partially correlated with recurrent AF in the first year (Spearman’s \( \rho = 0.59 \)) and in a weaker way with paroxysmal AF (Spearman’s \( \rho = -0.32 \)). As expected, recurrent AF was more common in patients who were not in sinus rhythm at the 12-month visit (Figure 3). None of the other mediators were correlated with sinus rhythm at 12 months (Spearman’s \( \rho = -0.22 \) to 0.13).

Effect of atrial fibrillation ablation (Objective 2)

Patients who underwent AF ablation were younger than patients treated without AF ablation (Table 3). The use of AF ablation did not affect
Table 1  Descriptive statistics of the potential mediators at 12 months by random group; restricted to patients without first primary endpoint and withdrawal of consent before first in-person follow-up visit at 12 months

|                          | Random group |   |   |   |   | P-value |
|--------------------------|--------------|---|---|---|---|---------|
|                          | Early rhythm control (n = 1257) | Usual care (n = 1260) | Total (n = 2517) |
| **Body mass index (calculated) (kg/m²)** | Median (IQR) | 28.4 (25.6–32.3) | 28.7 (25.6–32.5) | 28.6 (25.6–32.4) | 0.817 |
| Missing                  | 98 (8%)      | 102 (8%)           | 200 (8%)          |
| **Systolic blood pressure (mmHg)** | Median (IQR) | 140 (127–150) | 135 (125–150) | 138 (125–150) | <0.001 |
| Missing                  | 110 (9%)     | 98 (8%)            | 208 (8%)          |
| **Diastolic blood pressure (mmHg)** | Median (IQR) | 80 (71–88) | 80 (74–88) | 80 (73–88) | 0.971 |
| Missing                  | 110 (9%)     | 98 (8%)            | 208 (8%)          |
| **Suspected acute coronary syndrome** | 7/1178 (0.6%) | 4/1185 (0.3%) | 11/2363 (0.5%) | 0.130 |
| **AF recurrence(s) since last visit** | No | 816 (69.3%) | 718 (60.6%) | 1534 (64.9%) | <0.001 |
| Yes, one time            | 122 (10.4%)  | 130 (11.0%) | 252 (10.7%) |
| Yes, several times       | 190 (16.1%)  | 123 (10.4%) | 313 (13.2%) |
| Still in AF*             | 50 (4.2%)    | 214 (18.1%) | 264 (11.2%) |
| Missing                  | 79 (6%)      | 75 (6%)           | 154 (6%)          |
| **Type of AF**           | Paroxysmal   | 873 (77.5%) | 733 (75.5%) | 1606 (76.5%) | 0.079 |
| Persistent or long-standing persistent | 254 (22.5%) | 238 (24.5%) | 492 (23.5%) |
| Missing                  | 130 (10%)    | 289 (23%)        | 419 (16%)         |
| **Overall symptom score (EHRA)** | EHRA I | 875 (74.5%) | 843 (71.1%) | 1718 (72.8%) | 0.216 |
|                           | EHRA II | 263 (22.4%) | 302 (25.5%) | 565 (23.9%) |
|                           | EHRA III | 36 (3.1%)    | 39 (3.3%)     | 75 (3.2%)     |
|                           | EHRA IV | 1 (0.1%)     | 1 (0.1%)      | 2 (0.1%)      |
| Missing                  | 82 (7%)     | 75 (6%)        | 157 (6%)        |
| **Cardiac rhythm**       | Sinus rhythm | 977/1140 (85.7%) | 763/1150 (66.3%) | 1740/2290 (76.0%) | <0.001 |
| **Heart rate (b.p.m.)**  | Median (IQR) | 62 (57–71) | 64 (57–71) | 63 (57–71) | 0.461 |
| Missing                  | 252 (20%)   | 481 (38%)      | 733 (29%)       |
| **Ventricular rate in AF (average of 10 intervals)** | Median (IQR) | 80 (69–92) | 81 (71–94) | 81 (71–94) | 0.161 |
| Missing                  | 1123 (89%)  | 889 (71%)      | 2012 (80%)      |
| **Bundle branch block**  | 156/1103 (14.1%) | 124/1124 (11.0%) | 280/2227 (12.6%) | 0.010 |
| **AV nodal block**       | 203/1093 (18.6%) | 151/1096 (13.8%) | 354/2189 (16.2%) | <0.001 |
| **INR value**            | Median (IQR) | 1.3 (1.1–2.1) | 1.4 (1.1–2.1) | 1.3 (1.1–2.1) | 0.277 |
| Missing                  | 469 (37%)   | 426 (34%)      | 895 (36%)       |
| **PT value (seconds)**   | Median (IQR) | 57 (32–88) | 58 (33–87) | 57 (32–87) | 0.852 |
| Missing                  | 673 (54%)   | 638 (51%)      | 1311 (52%)      |

*p-values of the treatment effect on the respective potential mediator, adjusted for baseline characteristics, and the respective baseline measurement, if one was available (there was no baseline measurement available for AF recurrence(s) since last visit).
IQR, interquartile range.
*No documented SR in between.
the primary outcome of the trial (Figure 4). Older age, presence of heart failure, peripheral or severe coronary artery disease, and a lower physical component of the SF-12 score had clear effects on the primary outcome (Figure 4, Table 4).

**Effect of atrial fibrillation ablation as a component of early rhythm control (Objective 3)**

A total of 340/1395 (24%) patients randomized to ERC therapy underwent AF ablation. Similar to the analysis in the entire population (Figure 4), older age, heart failure, and peripheral or severe coronary artery disease had clear effects on the primary outcome (Figure 5, all \( P \leq 0.05 \)). In an exploratory analysis of the timing of AF ablation, 98 patients underwent early AF ablation as first-line therapy within the protocol-specified period. Compared with non-ablated time intervals within patients randomized to ERC, cardiovascular outcomes appeared reduced in time intervals after early ablation within 8 weeks after randomization (HR 0.66, 95% CI 0.35–1.25; Figure 5). Atrial fibrillation ablation at a later time was associated with increased cardiovascular outcomes (HR 1.27, 95% CI 0.87–1.84 compared with non-ablated time intervals).

**Discussion**

This prespecified, hypothesis-generating analysis of the EAST-AFNET 4 trial data set identified factors and mediators of ERC that were associated with reduced cardiovascular outcomes. Key findings are: (i) sinus rhythm at 12 months explained 81% of the treatment effect of ERC compared with usual care during the remainder of follow up; (ii) these analyses confirm that the effectiveness of the ERC therapy strategy tested in EAST-AFNET 4 relies on attaining sinus rhythm. Consequently, ERC therapy should aim for early and sustained restoration of sinus rhythm in patients with recently diagnosed AF to improve cardiovascular outcomes; and (iii) in the EAST-AFNET 4 trial setting where AF ablation was readily available when needed, the use of AF ablation was not associated with better outcomes than antiarrhythmic drug therapy (Structured Graphical Abstract). Future trials assessing the effectiveness and safety of early AF ablation in patients with cardiovascular comorbidities are warranted.

**Sinus rhythm at 12 months explains most of the effect of early rhythm control**

Our main modelling analysis demonstrates that the presence of sinus rhythm at 12 months, the first follow-up interval with rhythm assessment in all patients, explains 81% of the outcome reduction achieved with ERC. This is an important mechanistic confirmation of the initial hypothesis of EAST-AFNET 4: restoring and maintaining sinus rhythm is the predominant effect of the ERC strategy in EAST-AFNET 4. Earlier trials comparing rate control limited to antiarrhythmic drug therapy and cardioversion did not show reduced outcomes in patients randomized to rhythm control therapy.11,12 However, a modelling analysis of the AFFIRM data
Table 2  Results of mediation analyses for three selected mediators and the three endpoints

| Mediator/effect                                      | Primary endpoint \( (n = 2517) \) | Cardiovascular death \( (n = 2635) \) | Stroke \( (n = 2616) \) |
|-----------------------------------------------------|-------------------------------------|---------------------------------------|-------------------------|
|                                                     | HR  95% CI  Proportion eliminated  | HR  95% CI  Proportion eliminated  | HR  95% CI  Proportion eliminated |
|-----------------------------------------------------|-------------------------------------|---------------------------------------|-------------------------|
| **Sinus rhythm at 12-month visit**                  |                                     |                                       |                         |
| Total effect                                        | 0.73  0.61–0.92                    | 0.72  0.52–1.15                      | 0.61  0.41–1.18         |
| Natural direct effect                               | 0.77  0.64–0.97                    | 0.78  0.57–1.23                      | 0.67  0.46–1.26         |
| Controlled direct                                   |                                     |                                       |                         |
| In sinus rhythm at 12 months                        | 0.70  0.57–0.90                    | 0.71  0.49–1.27                      | 0.58  0.38–1.31         |
| Not in sinus rhythm at 12 months                   | 0.94  0.65–1.67  0.81              | -0.46 to 2.07                        | 0.95  0.57–2.81  0.84   | -0.95 to 2.64                        | 0.91  0.52–3.79  0.85   | -0.41 to 2.11 |
| **AF recurrence up to 12-month visit**             |                                     |                                       |                         |
| Total effect                                        | 0.74  0.62–0.93                    | 0.73  0.53–1.15                      | 0.63  0.42–1.25         |
| Natural direct effect                               | 0.75  0.62–0.94                    | 0.74  0.54–1.16                      | 0.65  0.44–1.26         |
| Controlled direct                                   |                                     |                                       |                         |
| Without AF rec. up to 12 months                    | 0.71  0.57–0.94                    | 0.71  0.48–1.35                      | 0.61  0.37–1.75         |
| With AF rec. up to 12 months                       | 0.81  0.61–1.19  0.31              | -0.64 to 1.26                        | 0.79  0.51–1.68  0.26   | -1.37 to 1.89                        | 0.73  0.47–1.65  0.26   | -1.37 to 1.89 |
| **Systolic blood pressure at 12-month visit**      |                                     |                                       |                         |
| Total effect                                        | 0.72  0.60–0.91                    | 0.75  0.55–1.18                      | 0.73  0.48–1.46         |
| Natural direct effect                               | 0.72  0.59–0.91                    | 0.76  0.56–1.20                      | 0.73  0.49–1.48         |
| Controlled direct                                   |                                     |                                       |                         |
| At 135 mmHg\(^b\) at 12 months                     | 0.72  0.60–0.91                    | 0.76  0.56–1.19                      | 0.71  0.48–1.32         |
| At 139 mmHg\(^c\) at 12 months                     | 0.74  0.62–0.93  0.10              | -0.06 to 0.26                        | 0.74  0.55–1.17  -0.04 | -0.31 to 0.23                        | 0.67  0.47–1.20  -0.30 | -1.14 to 0.54 |

The analyses are adjusted for baseline characteristics that may confound the treatment effects on the mediator or the mediator effect on the outcome. Total effect indicates the adjusted treatment effect on the outcome; natural direct effect indicates the adjusted treatment effect due to the observed distribution of the mediator; controlled direct effects indicate the adjusted treatment effect for subgroups of patients at a specified value of the mediator; and proportion eliminated is the proportion of the total effect that is due to variations of the mediator.

\(^a\)Additionally adjusted for systolic blood pressure at baseline.

\(^b\)The median value of the UC group at 12 months.

\(^c\)The median value of the ERC group at 12 months.
A similar association of presence of sinus rhythm with better outcomes compared with patients who remained in AF was observed in the AF sub-study of the DIAMOND trial. These prior analyses are in line with our analysis and underline the outstanding role of sinus rhythm for prognosis in AF patients. As a snapshot, the 12-month ECG follow-up, even though it only provides a very crude estimate of AF burden and recurrent AF, identified patients in whom ERC therapy was not successful. These patients did not show reduced primary outcome events in our landmark analysis (Figure 3). Atrial fibrillation recurrence during the first year of follow up explained a smaller portion of the therapy effect. Broadly speaking, patients with recurrent AF are either patients in whom another attempt at rhythm control is successful (leading to sinus rhythm at 12 months), or patients in whom rhythm control remains futile (resulting in AF at 12 months). The former group is likely to see the beneficial effects of ERC, the latter probably not. This consideration can explain the weaker effect of recurrent AF on cardiovascular outcomes compared with attaining sinus rhythm at 12 months.

By identifying sinus rhythm during the initial follow up as the major mediator of the effectiveness of rhythm control therapy, our analysis provides a physiological rationale for ERC in routine care. The safety of ERC has been replicated in several analyses of large record data sets in South Korea, the USA, and in the UK Biobank. Consistent with our observation, randomization to the antiarrhythmic drug dronedarone was associated with reduced cardiovascular mortality and less ischemic strokes (HR 0.66; 95% CI 0.45–0.96) in a subanalysis of the ATHENA trial (a placebo-controlled, double-blind, parallel arm trial to assess the efficacy of dronedarone 400 mg twice daily for the prevention of cardiovascular hospitalization or death from any cause in patients with AF/atrial flutter). In addition to reducing a primary outcome of death or cardiovascular hospitalization, the lack of effectiveness of dronedarone in the subsequent PALLAS study, where dronedarone therapy without restoration of sinus rhythm was associated with worse cardiovascular outcomes, can be aligned with our analysis. Based on this analysis, and consistent with explorative analyses of earlier trials, achieving sinus rhythm is the key mediator of ERC leading to reduced cardiovascular complications.

Figure 3 Time to recurrent atrial fibrillation and number of patients with recurrent atrial fibrillation in patients randomized to early rhythm control by rhythm status at 12 months. (A) The survival curves show the time to recurrent atrial fibrillation from randomization to 12 months in patients randomized to early rhythm control who were in sinus rhythm at 12 months and for patients who were not in sinus rhythm at 12 months. Patients who reached a primary outcome event or died in the first 12 months were not included. Recurrent atrial fibrillation was documented by triggered visits due to atrial fibrillation in the telemetric echocardiography or by an unscheduled visit due to clinically documented atrial fibrillation. (B) The tabulated data show the proportion of patients without recurrent atrial fibrillation and with recurrent atrial fibrillation who were in sinus rhythm at the 12-month visit: 58.3% (105/180) of patients not in sinus rhythm at 12 months had a scheduled or unscheduled visit due to recurrent atrial fibrillation, while only 28.5% (288/1009) of those in sinus rhythm at 12 months had such a visit.

Atrial fibrillation ablation as a component of early rhythm control

Atrial fibrillation ablation was readily available for all patients randomized to ERC therapy within EAST-AFNET 4. Early rhythm control was often initiated using antiarrhythmic drugs (1211/1395 patients; 87%). Overall, ablation was used in 340/1395 (24%) of the patients randomized to ERC in EAST-AFNET 4. This underpins that AF ablation was a necessary component of the ERC strategy but also highlights that most patients were treated without AF ablation. Atrial fibrillation ablation creates durable rhythm control in many patients and is more effective in maintaining sinus rhythm than antiarrhythmic drugs. Studies in selected patients with severe heart failure and AF suggested that AF ablation could improve outcomes and there is good evidence that AF ablation improves left ventricular function. These data led many to speculate that ablation-based rhythm control therapy would improve outcomes compared with antiarrhythmic drug-based rhythm control. Our exploratory analysis did not find that AF ablation was associated with better outcomes than antiarrhythmic drug therapy. Our analysis is supported by the neutral main finding of the CABANA trial, a randomized study comparing AF ablation to rhythm control based on antiarrhythmic drugs. An exploratory analysis of CABANA suggested that AF ablation may improve cardiovascular outcomes in young patients with fewer comorbidities. A post hoc subanalysis of the EAST-AFNET 4 trial, in contrast, demonstrated a strong
Table 3 Baseline demographic and clinical characteristics of all patients according to ablation or no ablation by treatment group. Patients summarised as “ablation” underwent atrial fibrillation ablation at any time point during the follow-up.

|                          | Ablation | No ablation |
|--------------------------|----------|-------------|
|                          | ERC (n = 340) | UC (n = 168) | Total (n = 508) | ERC (n = 1055) | UC (n = 1226) | Total (n = 2281) |
| **Age (years)**          |          |             |               |              |              |               |
| Median (IQR)             | 68 (62–73) | 68 (64–72)  | 68 (63–73)    | 72 (66–77)   | 72 (66–77)   | 72 (66–77)    |
| ≥ 75 years               | 54 (15.9%) | 18 (10.7%)  | 72 (14.2%)    | 349 (33.1%)  | 391 (31.9%)  | 740 (32.4%)   |
| **Male sex**             |          |             |               |              |              |               |
| ERC                      | 183 (53.8%) | 89 (53.0%)  | 272 (53.5%)   | 567 (53.7%)  | 657 (53.6%)  | 1224 (53.7%)  |
| UC                       | 34 (10.7%)  | 10 (6.0%)   | 44 (8.7%)     | 67 (6.4%)    | 57 (4.7%)    | 124 (5.4%)    |
| **Weight (kg)**          |          |             |               |              |              |               |
| Median (IQR)             | 84 (75–98) | 82 (73–96)  | 84 (74–97)    | 80 (72–94)   | 84 (72–95)   | 83 (72–95)    |
| Missing                  | 2 (0.6%)  | 2 (0.4%)    | 5 (0.5%)      | 5 (0.4%)     | 5 (0.4%)     | 10 (0.4%)     |
| **AF characteristics**   |          |             |               |              |              |               |
| Type of AF               |          |             |               |              |              |               |
| First episode            | 110 (32.4%) | 57 (33.9%)  | 167 (32.9%)   | 418 (39.8%)  | 463 (37.8%)  | 881 (38.7%)   |
| Paroxysmal               | 110 (32.4%) | 56 (33.3%)  | 166 (32.7%)   | 391 (37.2%)  | 437 (35.6%)  | 828 (36.4%)   |
| Persistent or long-standing | 120 (35.3%) | 55 (32.7%)  | 175 (34.4%)   | 242 (23.0%)  | 326 (26.6%)  | 568 (24.9%)   |
| Missing                  | 4 (0.4%)  | 4 (0.2%)    | 6 (0.6%)      | 1 (0.1%)     | 7 (0.3%)     | 1 (0.1%)      |
| Heart rhythm             |          |             |               |              |              |               |
| Atrial fibrillation or atrial flutter | 193 (56.8%) | 70 (41.7%)  | 263 (51.8%)   | 434 (41.4%)  | 580 (47.3%)  | 1014 (44.6%)  |
| Sinus rhythm and pacing  | 147 (43.2%) | 98 (58.3%)  | 245 (48.2%)   | 615 (58.6%)  | 645 (52.7%)  | 1260 (55.4%)  |
| Missing                  | 6 (0.6%)  | 1 (0.1%)    | 7 (0.3%)      | 1 (0.1%)     | 7 (0.3%)     | 1 (0.1%)      |
| Duration of AF history at baseline (days) | 42 (6–123) | 39 (7–140)  | 41 (6–136)    | 34 (6–108)   | 36 (5–106)   | 35 (6–107)    |
| Med (IQR)                | 42 (6–123) | 39 (7–140)  | 41 (6–136)    | 34 (6–108)   | 36 (5–106)   | 35 (6–107)    |
| Missing                  | 2 (0.2%)  | 1 (0.1%)    | 3 (0.1%)      | 1 (0.1%)     | 3 (0.1%)     | 1 (0.1%)      |
| Overall symptom score (EHRA) |          |             |               |              |              |               |
| EHRA I (asympt.)        | 99 (31.1%) | 38 (24.2%)  | 137 (28.8%)   | 296 (30.0%)  | 368 (31.4%)  | 664 (30.8%)   |
| EHRA II                  | 156 (49.1%) | 84 (53.5%)  | 240 (50.5%)   | 510 (51.7%)  | 608 (51.9%)  | 1118 (51.8%)  |
| EHRA III                 | 62 (19.5%)  | 33 (21.0%)  | 95 (20.0%)    | 168 (17.0%)  | 184 (15.7%)  | 352 (16.3%)   |
| EHRA IV                  | 1 (0.3%)   | 2 (1.3%)    | 3 (0.6%)      | 13 (1.3%)    | 11 (0.9%)    | 24 (1.1%)     |
| Missing                  | 22 (6%)    | 11 (7%)     | 33 (6%)       | 68 (6%)      | 55 (4%)      | 123 (5%)      |
| Previous pharmacological or electrical cardioversion | 143/334 (42.8%) | 83/168 (49.4%) | 226/502 (45.0%) | 403/1030 (39.1%) | 460/1221 (37.7%) | 863/2251 (38.3%) |
| Median (IQR)             | 44 (40–49) | 44 (39–49)  | 44 (40–49)    | 42 (38–48)   | 43 (39–48)   | 43 (38–48)    |
| LA diastolic diameter (max diameter) (mm) | 51 (15%) | 25 (15%) | 76 (15%) | 141 (13%) | 165 (13%) | 306 (13%) |
| Missing                  | 51 (15%)  | 25 (15%)    | 76 (15%)      | 141 (13%)    | 165 (13%)    | 306 (13%)     |
| **Concomitant conditions** |          |             |               |              |              |               |
| Prior stroke or transient ischaemic attack | 42 (12.4%) | 19 (11.3%)  | 61 (12.0%)    | 133 (12.6%)  | 134 (10.9%)  | 267 (11.7%)   |
| MOCA total score         | 27 (24–29) | 27 (25–29)  | 27 (24–29)    | 26 (23–28)   | 26 (23–28)   | 26 (23–28)    |
| Missing                  | 8 (2.4%)   | 5 (3.0%)    | 13 (2.6%)     | 61 (5.8%)    | 48 (3.9%)    | 109 (4.8%)    |
| At least mild cognitive impairment (MOCA < 26) | 129 (38.9%) | 55 (33.7%)  | 184 (37.2%)   | 453 (45.6%)  | 529 (44.9%)  | 982 (45.2%)   |

Continued
Table 3  
Continued

| Condition                                      | Ablation       | No ablation     |
|------------------------------------------------|----------------|-----------------|
| Arterial hypertension                         | ERC (n = 340)  | UC (n = 168)    | Total (n = 508) | ERC (n = 1055) | UC (n = 1226) | Total (n = 2281) |
| Systolic blood pressure (mmHg)                | 307 (90.3%)    | 145 (86.3%)     | 452 (89.0%)     | 923 (87.5%)    | 1075 (87.7%)  | 1998 (87.6%)     |
| Diastolic blood pressure (mmHg)               | 138 (126–150)  | 135 (123–149)   | 136 (125–150)   | 133 (120–148)  | 137 (123–150) | 135 (121–150)    |
| Stable heart failure (NYHA Stage II or LVEF < 50%) | 80 (75–90)     | 80 (72–88)      | 80 (75–90)      | 80 (71–90)     | 80 (74–90)    | 80 (73–90)       |
| Heart failure (NYHA classification)            | 219 (64.4%)    | 110 (65.5%)     | 329 (64.8%)     | 686 (65.3%)    | 804 (65.6%)   | 1490 (65.5%)     |
| Severe coronary artery disease               | 64 (18.8%)     | 29 (17.3%)      | 93 (18.3%)      | 179 (17.0%)    | 207 (16.9%)   | 386 (16.9%)      |
| Peripheral artery disease                     | 18 (5.3%)      | 4 (2.4%)        | 22 (4.3%)       | 30 (4.3%)      | 55 (4.3%)     | 100 (4.4%)       |
| Diabetes                                      | 87 (25.6%)     | 30 (17.9%)      | 117 (23.0%)     | 264/1050 (25.1%) | 313 (25.5%) | 577/2276 (25.4%) |
| History of valve replacement                  | 1 (0.3%)       | 2 (1.2%)        | 3 (0.6%)        | 10/1050 (1.0%) | 10 (0.8%)     | 20/2276 (0.9%)   |
| CHA2DS2-Vasc score                            | 3.0 (2.0–4.0)  | 3.0 (2.0–4.0)   | 3.0 (2.0–4.0)   | 3.0 (2.0–4.0)  | 3.0 (2.0–4.0) | 3.0 (2.0–4.0)    |
| Left ventricular hypertrophy on echocardiography | 18 (5.3%)      | 10 (6.0%)       | 28 (5.5%)       | 47 (4.5%)      | 57 (4.6%)     | 104 (4.6%)       |
| Signs of valvular disease                     | 160 (47.1%)    | 78 (46.4%)      | 238 (46.9%)     | 449/1049 (42.8%) | 564/1223 (46.1%) | 1013/2272 (44.6%) |
| Hb value (g/L)                                | 145 (135–152)  | 143 (134–150)   | 144 (134–152)   | 142 (132–151)  | 142 (132–151) | 142 (132–151)    |
| Chronic kidney disease (MDRD Stage III or IV) | 29 (8.5%)      | 12 (7.1%)       | 41 (8.1%)       | 143 (13.6%)    | 167 (13.6%)   | 310 (13.6%)      |
| GFR (MDRD formula)                            | 76 (66–89)     | 75 (65–85)      | 76 (66–87)      | 76 (63–89)     | 76 (63–89)    | 76 (63–89)       |
| Chronic obstructive pulmonary disease          | 22 (6.5%)      | 10 (6.0%)       | 32 (6.3%)       | 73/1048 (7.0%) | 104/1218 (8.5%) | 177/2266 (7.8%)  |
| Malignant diseases                            | 316 (93.2%)    | 160 (95.2%)     | 476 (93.9%)     | 954 (91.1%)    | 1133 (92.5%)  | 2087 (91.9%)     |
| Yes, currently under therapy                  | 2 (0.6%)       | 0 (0.0%)        | 2 (0.4%)        | 6 (0.6%)       | 11 (0.9%)     | 17 (0.7%)        |
| Yes, not under current therapy                | 21 (6.2%)      | 8 (4.8%)        | 29 (5.7%)       | 87 (8.3%)      | 81 (6.6%)     | 168 (7.4%)       |
| Thyroid dysfunction (hypo- or hyperthyroidism)| 43 (12.6%)     | 14 (8.3%)       | 57 (11.2%)      | 101/1050 (9.6%) | 104 (8.5%)    | 205/2276 (9.0%)  |

Continued
### Table 3  Continued

| Medication at discharge                                  | ERC (n = 340) | UC (n = 168) | Total (n = 508) | ERC (n = 1055) | UC (n = 1226) | Total (n = 2281) |
|----------------------------------------------------------|---------------|--------------|-----------------|----------------|---------------|-----------------|
| Missings                                                 | 6 (0.6%)      | 1 (0.1%)     | 7 (0.3%)        | 67 (5.5%)      | 99 (4.4%)     | 166 (7.3%)      |
| Digoxin or digitoxin                                     | 14 (4.1%)     | 18 (10.7%)   | 32 (6.3%)       | 32 (3.1%)      | 67 (5.5%)     | 99 (4.4%)       |
| Beta blockers                                            | 280 (82.4%)   | 146 (86.9%)  | 426 (83.9%)     | 778 (74.2%)    | 1045 (85.3%)  | 1823 (80.2%)    |
| Calcium channel antagonists                              | 114 (33.5%)   | 54 (32.1%)   | 168 (33.1%)     | 304 (29.0%)    | 393 (32.1%)   | 697 (30.7%)     |
| ACE inhibitors or angiotensin II receptor blocker        | 242 (71.2%)   | 177 (69.6%)  | 359 (70.7%)     | 711 (67.8%)    | 862 (70.4%)   | 1573 (69.2%)    |
| Oral anticoagulation (NOAC & VKA)                       | 316 (92.9%)   | 152 (90.5%)  | 468 (92.1%)     | 951 (90.7%)    | 1098 (89.6%)  | 2049 (90.1%)    |
| Mineralocorticoid receptor antagonist at discharge       | 27 (7.9%)     | 15 (8.9%)    | 42 (8.3%)       | 63 (6.0%)      | 77 (6.3%)     | 140 (6.2%)      |
| Insulin                                                 | 19 (5.6%)     | 1 (0.6%)     | 20 (3.9%)       | 43 (4.1%)      | 58 (4.7%)     | 101 (4.4%)      |
| Oral antidiabetic                                        | 51 (15.0%)    | 22 (13.1%)   | 73 (14.4%)      | 177 (16.9%)    | 209 (17.1%)   | 386 (17.0%)     |
| Diuretics                                               | 145 (42.6%)   | 60 (35.7%)   | 205 (40.4%)     | 414 (39.5%)    | 501 (40.9%)   | 915 (40.2%)     |
| Antianginal drugs                                        | 4 (1.2%)      | 1 (0.6%)     | 5 (1.0%)        | 9 (0.9%)       | 10 (0.8%)     | 19 (0.8%)       |
| Statin                                                  | 162 (47.6%)   | 67 (39.9%)   | 229 (45.1%)     | 466 (44.4%)    | 501 (40.9%)   | 967 (42.5%)     |
| Inhibitor of platelet aggregation                        | 59 (17.4%)    | 26 (15.5%)   | 85 (16.7%)      | 170 (16.2%)    | 200 (16.3%)   | 370 (16.3%)     |

IQR, interquartile range.

*Previous myocardial infarction, CABG, or PCI.

*15 mm wall thickness.

With currently active disease manifestation.

Without active disease manifestation.
beneficial effect of ERC in patients with multiple comorbidities, without a detectable effect of age. Given that AF ablation has so far mainly been evaluated in younger AF patients, dedicated clinical trials testing the effectiveness and safety of an AF ablation-dominated rhythm control strategy in patients with multiple comorbidities are needed, potentially utilizing simple ‘single-shot’ devices.

Figure 4 Association of atrial fibrillation ablation and primary outcome for all patients: results of an adjusted Cox model with ablation as a time-dependent predictor and its interaction with treatment, and random effect for centre (n = 2789, events = 565).
Table 4  Baseline demographic and clinical characteristics of patients randomized to early rhythm control and undergoing no atrial fibrillation ablation, early atrial fibrillation ablation, or late atrial fibrillation ablation. Early atrial fibrillation ablation was defined as ablation as first-line rhythm control therapy used within the protocol-defined time period.

| No ablation (n = 1055) | Early ablation (n = 98) | Late ablation (n = 242) | Total (n = 1395) |
|------------------------|------------------------|------------------------|------------------|
| Age (years) Median (IQR) | 72 (66–77) | 67 (61–74) | 68 (63–73) | 71 (65–76) |
| Male sex | 567 (53.7%) | 55 (56.1%) | 128 (52.9%) | 750 (53.8%) |
| Weight (kg) Median (IQR) | 82 (72–94) | 85 (76.9–95) | 84 (74–98) | 82 (72–95) |
| ≥ 75 years | 349 (33.1%) | 21 (21.4%) | 33 (13.6%) | 403 (28.9%) |
| Male sex | 567 (53.7%) | 55 (56.1%) | 128 (52.9%) | 750 (53.8%) |
| Type of AF First episode | 418 (39.8%) | 26 (26.5%) | 84 (34.7%) | 528 (38.0%) |
| Persistent or long-standing persistent | 242 (23.0%) | 37 (37.8%) | 83 (34.3%) | 362 (26.0%) |
| Missing | 5 (0.5%) | 1 (1.0%) | 1 (0.4%) | 7 (0.5%) |
| Heart rhythm Atrial fibrillation or atrial flutter | 4346 (41.4%) | 556 (56.1%) | 138 (57.0%) | 627 (45.1%) |
| Sinus rhythm and pacing | 6156 (58.6%) | 43 (43.9%) | 104 (43.0%) | 762 (54.9%) |
| Missing | 6 (0.6%) | 4 (0.4%) | 0 (0%) | 10 (0.7%) |
| Duration of AF history at baseline (days) Median (IQR) | 34 (6–108) | 45 (8–180) | 42 (5–118) | 36 (6–114) |
| Missing | 2 (0.2%) | 2 (0.2%) | 1 (0.4%) | 5 (0.3%) |
| Overall symptom score (EHRA) EHRA I (asymptomatic) | 296 (30.0%) | 22 (25.3%) | 77 (33.3%) | 395 (30.3%) |
| EHRA II | 510 (51.7%) | 46 (52.9%) | 110 (47.6%) | 666 (51.0%) |
| EHRA III | 168 (17.0%) | 19 (21.8%) | 43 (18.6%) | 230 (17.6%) |
| EHRA IV | 13 (1.3%) | 0 (0.0%) | 1 (0.4%) | 14 (1.1%) |
| Missing | 68 (6%) | 11 (11%) | 11 (5%) | 90 (6%) |
| LA diastolic diameter (max diameter) (mm) Median (IQR) | 42 (38–48) | 45 (40–50) | 44 (40–49) | 43 (38–48) |
| Missing | 141 (13%) | 19 (19%) | 32 (13%) | 192 (14%) |
| Previous pharmacological or electrical cardioversion 403/1030 (39.1%) | 42/96 (43.8%) | 101/238 (42.4%) | 546/1364 (40.0%) |
| MOCA total score Median (IQR) | 26 (23–28) | 27 (24–29) | 27 (24–29) | 26 (23–28) |
| MOCA total score Missing | 61 (6%) | 4 (4%) | 4 (2%) | 69 (5%) |
| At least mild cognitive impairment (MOCA < 26) | 453 (45.6%) | 39 (41.5%) | 90 (37.8%) | 582 (43.9%) |
| Arterial hypertension | 923 (87.5%) | 87 (88.8%) | 220 (90.9%) | 1230 (88.2%) |
Table 4  Continued

|                                         | No ablation (n = 1055) | Early ablation (n = 98) | Late ablation (n = 242) | Total (n = 1395) |
|-----------------------------------------|------------------------|-------------------------|--------------------------|-----------------|
| Systolic blood pressure (mmHg)          | Median (IQR)           |                         |                          |                 |
|                                        | 133 (120–148)          | 130 (122–145)           | 140 (129–150)           | 135 (122–150)   |
|                                        | 6 (0.6%)               | 3 (1.2%)                | 9 (0.6%)                |                 |
| Dastolic blood pressure (mmHg)          | Median (IQR)           |                         |                          |                 |
|                                        | 80 (71–90)             | 80 (74–86)              | 80 (76–90)              | 80 (73–90)      |
|                                        | 6 (0.6%)               | 3 (1.2%)                | 9 (0.6%)                |                 |
| Stable heart failure (NYHA Stage II or LVEF < 50%) |                  |                         |                          |                 |
|                                        | 308 (29.2%)            | 28 (28.6%)              | 60 (24.8%)              | 396 (28.4%)     |
| Heart failure (NYHA classification)     | No heart failure       |                         |                          |                 |
|                                        | 686 (65.3%)            | 60 (61.2%)              | 159 (65.7%)             | 905 (65.1%)     |
|                                        | 116 (11.0%)            | 14 (14.3%)              | 35 (14.5%)              | 165 (11.9%)     |
|                                        | 196 (18.7%)            | 20 (20.4%)              | 39 (16.1%)              | 255 (18.3%)     |
|                                        | 52 (5.0%)              | 4 (4.1%)                | 9 (3.7%)                | 65 (4.7%)       |
|                                        | 5 (0.5%)               |                         |                         | 5 (0.4%)        |
| Severe coronary artery disease          |                        |                         |                          |                 |
|                                        | 179 (17.0%)            | 16 (16.3%)              | 48 (19.8%)              | 243 (17.4%)     |
| Peripheral artery disease              | 45 (4.3%)              | 5 (5.1%)                | 13 (5.4%)               | 63 (4.5%)       |
| Diabetes                               | 264/1050 (25.1%)       | 21 (21.4%)              | 66 (27.3%)              | 351/1390 (25.3%)|
| History of valve replacement            | 10/1050 (1.0%)         | 1 (1.0%)                | 0 (0.0%)                | 11/1390 (0.8%)  |
| CHA2DS2-VASC score                     | Median (IQR)           |                         |                          |                 |
|                                        | 3.0 (2.0–4.0)          | 3.0 (2.0–4.0)           | 3.0 (2.0–4.0)           | 3.0 (2.0–4.0)   |
| Left ventricular hypertrophy on echocardiography |           |                         |                          |                 |
|                                        | 47 (4.5%)              | 6 (6.1%)                | 12 (5.0%)               | 65 (4.7%)       |
| Signs of valvular disease              | 449/1049 (42.8%)       | 53 (54.1%)              | 107 (44.2%)             | 609/1389 (43.8%)|
| Hb value (g/L)                         | Median (IQR)           |                         |                          |                 |
|                                        | 142 (132–151)          | 146 (135–153)           | 143 (135–152)           | 142 (133–151)   |
|                                        | 19 (2%)                | 1 (1%)                  | 5 (2%)                  | 25 (2%)         |
| Chronic kidney disease (MDRD Stage III or IV) |             |                         |                          |                 |
|                                        | 143 (13.6%)            | 4 (4.1%)                | 25 (10.3%)              | 172 (12.3%)     |
| GFR (MDRD formula)                     | Median (IQR)           |                         |                          |                 |
|                                        | 75.7 (63.7–88.9)       | 77.6 (68.7–96.1)        | 75.0 (65.2–87.3)        | 75.7 (64.4–88.8)|
|                                        | 20 (2%)                | 3 (3%)                  | 4 (2%)                  | 27 (2%)         |
| Chronic obstructive pulmonary disease   | 73/1048 (7.0%)         | 5 (5.1%)                | 17 (7.0%)               | 95/1388 (6.8%)  |
| Malignant diseases                      | No                     |                         |                          |                 |
|                                        | 954 (91.1%)            | 93 (95.9%)              | 223 (92.1%)             | 1270 (91.6%)    |
|                                        | 6 (0.6%)               | 0 (0.0%)                | 2 (0.8%)                | 8 (0.6%)        |
|                                        | 87 (8.3%)              | 4 (4.1%)                | 17 (7.0%)               | 108 (7.8%)      |
|                                        | 8 (0.8%)               | 1 (1%)                  |                         | 9 (0.6%)        |

Continued
Table 4  Continued

| Drug Category                                      | No ablation (n = 1055) | Early ablation (n = 98) | Late ablation (n = 242) | Total (n = 1395) |
|----------------------------------------------------|------------------------|-------------------------|-------------------------|------------------|
| Thyroid dysfunction (hypo- or hyperthyroidism)     |                        |                         |                         |                  |
| 101/1050 (9.6%)                                    | 12 (12.2%)             | 31 (12.8%)              | 144/1390 (10.4%)       |                  |
| Medication at discharge                            |                        |                         |                         |                  |
| Missings                                           | 6 (0.6%)               | 6 (0.4%)                |                         |                  |
| Beta blockers                                      | 778 (74.2%)            | 85 (86.7%)              | 195 (80.6%)             | 1058 (76.2%)     |
| Calcium channel antagonists                        | 304 (29.0%)            | 30 (30.6%)              | 84 (34.7%)              | 418 (30.1%)      |
| ACE inhibitors or angiotensin ll receptor blocker  | 711 (67.8%)            | 71 (72.4%)              | 171 (70.7%)             | 953 (68.6%)      |
| Oral anticoagulation (NOAC & VKA)                 | 951 (90.7%)            | 95 (96.9%)              | 221 (91.3%)             | 1267 (91.2%)     |
| Mineralocorticoid receptor antagonist at discharge | 63 (6.0%)              | 7 (7.1%)                | 20 (8.3%)               | 90 (6.5%)        |
| Insulin                                            | 43 (4.1%)              | 5 (5.1%)                | 14 (5.8%)               | 62 (4.5%)        |
| Oral antidiabetic                                   | 177 (16.9%)            | 14 (14.3%)              | 37 (15.3%)              | 228 (16.4%)      |
| Diuretics                                          | 414 (39.5%)            | 42 (42.9%)              | 103 (42.6%)             | 559 (40.2%)      |
| Antianginal drugs                                   | 9 (0.9%)               | 1 (1.0%)                | 3 (1.2%)                | 13 (0.9%)        |
| Statin                                             | 466 (44.4%)            | 52 (53.1%)              | 110 (45.5%)             | 628 (45.2%)      |
| Inhibitor of platelet aggregation                  | 170 (16.2%)            | 17 (17.3%)              | 42 (17.4%)              | 229 (16.5%)      |

IQR, interquartile range.

\(^a\) Previous myocardial infarction, CABG or PCI.
\(^b\) >15 mm wall thickness.
\(^c\) Or with currently active disease manifestation.
\(^d\) And without active disease manifestation.
Figure 5 Association of early, late, or no atrial fibrillation ablation and primary outcome for patients randomized to early rhythm control: results of an adjusted Cox model with two time-dependent variables for early and late ablation as predictors and random effect for centre (n = 1395, events = 249).
What can be learned for the management of patients with atrial fibrillation at 1 year after initiation of early rhythm control therapy?

A systematic ERC therapy strategy reduced outcomes in the EAST-AFNET 4 trial.1,9 This outcome-reducing effect of ERC was achieved by delivering therapy with relatively few complications. This main finding should in our view guide the management of patients presenting in AF after 12 months of rhythm control therapy. There will be patients in this group in whom further rhythm control therapy can be delivered with an acceptable safety profile, e.g. a first or recurrent AF ablation, or a combination of AF ablation and antiarrhythmic drugs.29,30 In others, in whom multiple therapies and experimental treatment combinations may be needed, a treatment strategy of rate control only may be advisable. Future trials may explore the best therapy for patients who are not in sinus rhythm after 1 year of ERC. Until such trials report, a careful balance of the expected effectiveness and safety of further rhythm control therapy seems warranted.

Statistical considerations

An analysis using time-dependent covariates like the analysis presented here was also conducted within the AFFIRM trial.13 Differences in our analysis result from a different data structure: the date of AF ablation therapy was known while other potential mediators were only available at the two main follow-up visits (at 12 and 24 months). For these mediators, we used the causal mediation analysis approach to investigate the effect of them on the relationship between treatment and outcome. The classical approach introduced by Baron and Kenny29 and recently applied by Fitchett et al.32 was challenged by Valeri and Vanderweele33 who remarked that this approach does not allow causal interpretation in the presence of treatment–mediator interaction. The four-way decomposition used here allows the intended causal interpretation.

Limitations

The presented analyses are not bias protected by randomization. Thus, an extended adjustment of covariates was required, but could not replace a randomization that was not possible by design in this study. Although we considered all factors measured at the 12-month visit in our mediation analysis, unmeasured confounders may explain the effect seen in patients who were in sinus rhythm at the 12-month visit in this analysis. Our analysis identifies sinus rhythm at 12 months as the dominant factor for future outcomes. The number of triggered, therapy-related visits was small in the EAST-AFNET 4 population, but we cannot exclude that a structured follow-up regimen contributed to differences in clinical outcomes seen in the trial. We used all available information to adjust for differences in baseline characteristics between the groups compared in these subanalyses. Still there may be differences that we have failed to adjust for. Our analysis may suffer from hidden biases and other unidentified confounders. Future randomized studies evaluating, e.g. ablation-based ERC strategies, are warranted. Furthermore, the described approach examined the effect of the mediators independently of each other, one at a time. The relationship between different mediators cannot be identified by use of observational mediation models as the mediators are not randomized to the treatment groups.34

Conclusion

Successful rhythm control therapy, estimated by presence of sinus rhythm at 12 months after randomization, explains most of the reduction in cardiovascular outcomes achieved by ERC in the EAST-AFNET 4 trial. Based on these results, clinicians implementing ERC should aim for early and sustained restoration of sinus rhythm in patients with recently diagnosed AF and cardiovascular comorbidities. Further population-based investigations and clinical trials of AF management strategies may help to clarify the role of AF ablation and antiarrhythmic drug therapy for outcome reduction in patients with recently diagnosed AF and comorbidities.

Funding

EAST-AFNET 4 was supported by a grant from the German Ministry of Education and Research (01 GI 0204), the German Center for Cardiovascular Research (DZHK), the Atrial Fibrillation Network (AFNET), the European Heart Rhythm Association, St Jude Medical, Abbott, Sanofi, the German Heart Foundation, and Deutsche Herzstiftung (DHS). These analyses received additional support from the European Union (grant agreement 633196 (CATCH ME) to P.K. and AFNET; grant agreement EU IMI 116074 (BigData@Heart) to P.K.; and grant agreement 965286 (MAESTRIA) to AFNET), the British Heart Foundation (FS/13/43/30324, PG/17/13/32961, PG/20/22/35093, and AA/18/2/342118, to P.K.), and the Foundation Leducq (to P.K.). EAST-AFNET 4 ISRCTN number, ISRCTN04786880; ClinicalTrials.gov number, NCT01288352; EudraCT number, 2010-02158-20.

Conflict of interest: L.E. discloses consultant fees, speaking honoraria, and travel expenses from Abbott, Bayer Healthcare, Biosense Webster, Biotronik, Boehringer, Boston Scientific, Bristol-Myers Squibb, Daiichi Sankyo, Medtronic, Pfizer, and Sanofi Aventis. Research has been supported by German Research Foundation (DFG) and German Heart Foundation outside the submitted work. S.S. reports grants from AFNET, during the conduct of the study; grants from Biotronik, personal fees from Boston Scientific and grants from ResMed, outside the submitted work. A.S. reports grants from AFNET, during the conduct of the study; grants from Biotronik and grants from ResMed, outside the submitted work. K.B. declares that there is no conflict of interest. G.B. reports no potential conflicts of interest with regard to the present substudy of EAST. H.J.G.M.C. reports support from The Netherlands Cardiovascular Research Initiative: an initiative with support of the Dutch Heart Foundation, CVON 2014-9: reappraisal of atrial fibrillation: interaction between hypercoagulability, electrical remodelling, and vascular destabilization in the progression of AF (RACE V), outside this work. A.G. reports speaker and consulting fees from Bayer Health Care, Berlin Chemie, Boehringer Ingelheim, BMS/Pfizer, Boston Scientific, Daiichi Sankyo, Medtronic, Omeicos, and Menarini; grants from EU Horizon 2020 [grant no. 965286] and grants from AFNET, Sanofi-Aventis, and St Jude Medical during the conduct of the study. K.W. reports grants from AFNET, during the conduct of the study; grants from Biotronik, personal fees from Biotronik, personal fees from Boston Scientific and grants from ResMed and personal fees from Novartis, outside the submitted work. A.Z. reports grants from AFNET, during the conduct of the study; grants from Biotronik, personal fees from Boston Scientific and grants from ResMed, outside the submitted work. A.J.C. reports personal fees from Abbott and Sanofi and institutional grants from Abbott for work unrelated to the EAST trial. A.M. reports consulting fees from Medtronic and Biosense Webster; speaker fees from Medtronic, Biosense Webster, Boston Scientific, and Bayer; travel support from Medtronic and Boston Scientific. P.K. reports grants and nonfinancial support from BMBF (German Ministry of Education and Research), grants from Sanofi, grants from Abbott, grants and nonfinancial support from EHRA, grants from German Heart Foundation, grants from DZHK (German Center for Cardiovascular Research), during the conduct of the
study; grants from European Union, grants from British Heart Foundation, grants from Leducq Foundation, grants from Medical Research Council (UK), non-financial support from German Centre for Heart Research, outside the submitted work. In addition, P.K. has a patent Atrial Fibrillation Therapy WO 2015140571 issued to University of Birmingham, and a patent Markers for Atrial Fibrillation WO 2016012783 issued to University of Birmingham.

Data availability
Data are made available upon request. Please email info@kompetenznetz-vorhofflimmern.de with a proposal of planned analyses.

References
1. Kirchhof P, Camm AJ, Goette A, Brandes A, Eckardt L, Elvan A, et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med 2020;383:1305–1316.
2. Rillig A, Magnussen C, Ozga AK, Suling A, Brandes A, Breithardt G, et al. Early rhythm control therapy in patients with atrial fibrillation and heart failure. Circulation 2021;144:845–858.
3. Willems S, Borof K, Brandes A, Breithardt G, Camm AJ, Crijns H, et al. Systematic, early rhythm control strategy for patients in with or without symptoms: the EAST-AFNET 4 trial. Eur Heart J 2022;43:1219–1230.
4. Goette A, Borof K, Breithardt G, Camm AJ, Crijns H, Kuck K, et al. Presenting pattern of atrial fibrillation and outcomes of early rhythm control therapy. J Am Coll Cardiol 2022;80:283–295.
5. Dickow J, Kirchhof P, Van Houten HK, Sangaralingham LR, Dinshaw LHW, Friedman PA, et al. Generalizability of the EAST-AFNET 4 trial: assessing outcomes of early rhythm-control therapy in patients with atrial fibrillation. J Am Heart Assoc 2022;11:e024214.
6. Kany S, Cardoso VR, Bravo L, Williams JA, Schnabel R, Fabritz L, et al. Eligibility for early rhythm control in patients with atrial fibrillation in the UK BioBank. Heart 2022;heartjnl-2022-321196.
7. Camm AJ, Naccarelli GV, Mittal S, Crijns H, Hohnloser SH, Ma CS, et al. The increasing role of rhythm control in patients with atrial fibrillation: JACC State-of-the-art review. J Am Coll Cardiol 2022;79:1932–1948.
8. Schnabel R, Andreassi Marinelli E, Arbelo E, Boriani G, Boveda S, Buckley C, et al. Early diagnosis and better rhythm management to improve outcomes in patients with atrial fibrillation: the 8th AFNET/EHRA consensus conference. Europace 2022;essa062.
9. Metzner A, Suling A, Brandes A, Breithardt G, Camm AJ, Crijns H, et al. Anticoagulation, therapy of concomitant conditions, and early rhythm control therapy: a detailed analysis of treatment patterns in the EAST—AFNET 4 trial. EP Europace 2022;24:552–564.
10. White IR, Royston P, Wood AM. Multiple imputation using chained equations: issues and guidance for practice. Stat Med 2011;30:377–399.
11. Van Gelder I, Hagens VE, Bosker HA, Kingma H, Kamp O, Kingma T, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347:1834–1840.
12. Wyse DG, Waldo AL, DeMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347:1825–1833.
13. Corley SD, Epstein AE, DeMarco JP, Domanski MJ, Geller N, Greene HL, et al. Relationships between sinus rhythm, treatment, and survival in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Circulation 2004;109:1509–1513.
14. Pedersen OD, Bagger H, Keller N, Marchant B, Kober L, Torp-Pedersen C. Efficacy of dofetilide in the treatment of atrial fibrillation-flutter in patients with reduced left ventricular function: a Danish investigations of arrhythmia and mortality on dofetilide (diamone) substudy. Circulation 2001;104:292–296.
15. Kirchhof P, Bax J, Blomstrom-Lundqvist C, Calkins H, Camm AJ, Cappato R, et al. Early and comprehensive management of atrial fibrillation: executive summary of the proceedings from the 2nd AFNET-EHRA consensus conference ’research perspectives in AF’. Eur Heart J 2009;30:2969–2977c.
16. Fabritz L, Crijns H, Guasch E, Goette A, Hausler KG, Kotecha D, et al. Dynamic risk assessment to improve quality of care in patients with atrial fibrillation: the 7th AFNET/EHRA consensus conference. Europace 2021;23:329–344.
17. Kim D, Yang PS, You SC, Sung JH, Jang E, Yu HT, et al. Treatment timing and the effects of rhythm control strategy in patients with atrial fibrillation: nationwide cohort study. BMJ 2021;373:n991.
18. Connolly SJ, Crijns HJ, Torp-Pedersen C, van Eckels M, Gaudin C, Page RL, et al. Analysis of stroke in ATHENA: a placebo-controlled, double-blind, parallel-armed trial to assess the efficacy of dronedarone 400 mg BID for the prevention of cardiovascular hospitalization or death from any cause in patients with atrial fibrillation/atrial flutter. Circulation 2009;120:1174–1180.
19. Hohnloser SH, Crijns HJ, van Eckels M, Gaudin C, Page RL, Torp-Pedersen C, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009;360:668–678.
20. Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 2011;365:2268–2276.
21. Wazni OM, Dandamudi G, Sood N, Hoyt R, Tyler J, Dunnari S, et al. Cryoballoon ablation as initial therapy for atrial fibrillation. N Engl J Med 2021;384:316–324.
22. Andrade JG, Wells GA, Deyell MW, Bennett M, Essabel V, Champagne J, et al. Cryoballoon or drug therapy for initial treatment of atrial fibrillation. N Engl J Med 2021;384:305–315.
23. Marrouche NF, Brachmann J, Andresen D, Siebels J, Boersma L, Jordans L, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med 2018;378:417–427.
24. Willems S, Meyer C, de Bono J, Brandes A, Eckardt L, Elvan A, et al. Cabins, castles, and constant hearts: rhythm control therapy in patients with atrial fibrillation. Eur Heart J 2019;40:3793–3799c.
25. Packer DL, Mark DB, Robb RA, Monahan KH, Bahnson TD, Poole JE, et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA 2019;321:1261–1274.
26. Bahnson TD, Giczewska A, Mark DB, Russo AM, Monahan KH, Al-Khalidi HR, et al. Association between age and outcomes of catheter ablation versus medical therapy for atrial fibrillation: results from the CABANA trial. Circulation 2022;145:796–804.
27. Rillig A, Borof K, Breithardt G, Camm AJ, Crijns H, Goette A, et al. Early rhythm control in patients with atrial fibrillation and high comorbidity burden. Circulation 2021;144:845–858.
28. Kuck KH, Brugada J, Furnkranz A, Metzner A, Ouyang F, Chun KR, et al. Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation. N Engl J Med 2016;374:2233–2245.
29. Darker S, Chen X, Hansen J, Pehrson S, Johannesson A, Nielsen JB, et al. Recurrence of arrhythmia following short-term oral AMIODarone after CATHeter ablation for atrial fibrillation: a double-blind, randomized, placebo-controlled study (AMIO-CAT trial). Eur Heart J 2014;35:3356–3364.
30. Duytscheva M, Demolder A, Philips T, Sarkozy A, El Haddad M, Taghi J, et al. Pulmonary vein isolation with or without continued antiarrhythmic Drug treatment in subjects with Recurrent Atrial Fibrillation (POWDER AF): results from a multicentre randomized trial. Eur Heart J 2018;39:1429–1437.
31. Baron RM, Kenny DA. The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations. J Pers Soc Psychol 1986;51:1173–1182.
32. Fitchett D, Inzucchi SE, Zinman B, Wanner C, Schumacher M, Schmoor C, et al. Mediators of the improvement in heart failure outcomes with empagliflozin in the EMPA-REG OUTCOME trial. ESC Heart Fail 2021;8:4517–4527.
33. Valeri L, VanderWeele TJ. Mediation analysis allowing for exposure-mediator interactions and causal interpretation: theoretical assumptions and implementation with SAS and SPSS macros. Psychol Methods 2013;18:137–150.
34. VanderWeele TJ, Vansteelandt S. Mediation analysis with multiple mediators. Epidemiol Methods 2014;2:95–115.